Invivyd (NASDAQ:IVVD) Shares Up 6.1% – Should You Buy?

Shares of Invivyd, Inc. (NASDAQ:IVVD) shot up 6.1% during mid-day trading on Tuesday . The stock traded as high as $2.34 and last traded at $2.3550. 1,923,221 shares traded hands during trading, a decline of 75% from the average session volume of 7,673,814 shares. The stock had previously closed at $2.22.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on IVVD. Cantor Fitzgerald initiated coverage on shares of Invivyd in a research report on Monday, October 6th. They issued an “overweight” rating and a $10.00 price objective for the company. Zacks Research upgraded Invivyd from a “strong sell” rating to a “hold” rating in a research note on Thursday, November 13th. D Boral Capital downgraded shares of Invivyd from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 25th. Weiss Ratings reissued a “sell (e+)” rating on shares of Invivyd in a report on Monday. Finally, D. Boral Capital restated a “hold” rating on shares of Invivyd in a research note on Tuesday, November 25th. Two equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $7.33.

Invivyd Stock Performance

The company’s fifty day moving average is $2.08 and its 200-day moving average is $1.31.

Invivyd (NASDAQ:IVVD) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($0.06) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.01). Invivyd had a negative return on equity of 92.97% and a negative net margin of 119.63%.The firm had revenue of $13.13 million for the quarter, compared to analyst estimates of $12.00 million. On average, analysts anticipate that Invivyd, Inc. will post -1.64 earnings per share for the current year.

Insider Transactions at Invivyd

In related news, Director Kevin F. Mclaughlin purchased 50,000 shares of the firm’s stock in a transaction on Wednesday, November 19th. The stock was purchased at an average cost of $2.50 per share, for a total transaction of $125,000.00. Following the completion of the purchase, the director directly owned 50,000 shares in the company, valued at $125,000. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 25.40% of the company’s stock.

Institutional Trading of Invivyd

A number of large investors have recently added to or reduced their stakes in IVVD. Invesco Ltd. raised its position in shares of Invivyd by 190.6% in the first quarter. Invesco Ltd. now owns 108,999 shares of the company’s stock worth $66,000 after buying an additional 71,485 shares in the last quarter. Nuveen LLC bought a new stake in shares of Invivyd during the 1st quarter valued at about $65,000. AQR Capital Management LLC grew its holdings in shares of Invivyd by 2,051.0% during the first quarter. AQR Capital Management LLC now owns 410,711 shares of the company’s stock worth $249,000 after purchasing an additional 391,617 shares in the last quarter. Vanguard Personalized Indexing Management LLC increased its position in shares of Invivyd by 238.6% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 39,941 shares of the company’s stock worth $29,000 after purchasing an additional 28,146 shares during the last quarter. Finally, Catalyst Funds Management Pty Ltd purchased a new stake in Invivyd in the second quarter valued at approximately $27,000. Hedge funds and other institutional investors own 70.36% of the company’s stock.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.